DCR: 克罗恩病结肠切除术后联合使用免疫抑制剂会增加腹腔脓毒血症的概率

2018-11-16 MedSci MedSci原创

腹腔内败血症会使克罗恩病的回肠结肠切除术的复杂性大大提高,但联合免疫抑制和重复切除对其发展的影响仍然还不清楚。本研究的目的是确定回肠结肠切除术后腹腔内败血症的危险因素,特别是在使用联合免疫抑制和重复肠切除后腹腔内败血症的影响。

背景
腹腔内败血症会使克罗恩病的回肠结肠切除术的复杂性大大提高,但联合免疫抑制和重复切除对其发展的影响仍然还不清楚。本研究的目的是确定回肠结肠切除术后腹腔内败血症的危险因素,特别是在使用联合免疫抑制和重复肠切除后腹腔内败血症的影响。

方法
这项研究是一项回顾性临床分析,纳入的患者为诊断克罗恩病的患者,这些患者均接受了回结肠切除吻合术。主要观察指标为术前和术中变量包括术前免疫抑制方案和既往肠切除,对腹腔内败血症的影响情况。

结果
共有621名患者(55%的女性)接受了克罗恩病的回肠结肠切除术;393(63%)是首次切除。30天腹腔内败血症的发生率为8%(n = 50)。在单变量分析中,三重免疫抑制(皮质类固醇,免疫调节剂和生物学的组合)和先前的肠切除术与腹腔内败血症显着相关。两种风险因素在多变量分析中仍然显着(三重免疫抑制OR= 3.53(95%CI,1.27-9.84);之前的肠切除OR = 2.27(95%CI,1.25-4.13))。在先前肠切除术的数量增加和腹腔内败血症的发生率之间观察到明显增加的趋势(p<0.01)。

结论
联合免疫抑制和既往肠切除史均与腹腔内败血症的发生有关。鉴于这些结果,外科医生在决定哪些患者应该行回结肠切除吻合术的时候应考虑联合免疫抑制和既往肠切除病史以及其他危险因素的影响。

原始出处:
McKenna, Nicholas P. et al. Intra-abdominal Sepsis After Ileocolic Resection in?Crohn’s Disease. Diseases of the Colon & Rectum.2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1706551, encodeId=10eb1e06551f8, content=<a href='/topic/show?id=0df2e87477d' target=_blank style='color:#2F92EE;'>#结肠切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78747, encryptionId=0df2e87477d, topicName=结肠切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89f31292094, createdName=12498568m60暂无昵称, createdTime=Fri Apr 19 14:54:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851845, encodeId=a07b18518455c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 23 00:54:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877086, encodeId=54c318e70865f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 05 13:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353073, encodeId=dea73530e3ae, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Nov 19 19:26:03 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286285, encodeId=070b1286285c7, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Nov 18 02:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1706551, encodeId=10eb1e06551f8, content=<a href='/topic/show?id=0df2e87477d' target=_blank style='color:#2F92EE;'>#结肠切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78747, encryptionId=0df2e87477d, topicName=结肠切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89f31292094, createdName=12498568m60暂无昵称, createdTime=Fri Apr 19 14:54:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851845, encodeId=a07b18518455c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 23 00:54:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877086, encodeId=54c318e70865f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 05 13:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353073, encodeId=dea73530e3ae, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Nov 19 19:26:03 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286285, encodeId=070b1286285c7, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Nov 18 02:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
    2019-02-23 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1706551, encodeId=10eb1e06551f8, content=<a href='/topic/show?id=0df2e87477d' target=_blank style='color:#2F92EE;'>#结肠切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78747, encryptionId=0df2e87477d, topicName=结肠切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89f31292094, createdName=12498568m60暂无昵称, createdTime=Fri Apr 19 14:54:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851845, encodeId=a07b18518455c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 23 00:54:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877086, encodeId=54c318e70865f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 05 13:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353073, encodeId=dea73530e3ae, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Nov 19 19:26:03 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286285, encodeId=070b1286285c7, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Nov 18 02:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1706551, encodeId=10eb1e06551f8, content=<a href='/topic/show?id=0df2e87477d' target=_blank style='color:#2F92EE;'>#结肠切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78747, encryptionId=0df2e87477d, topicName=结肠切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89f31292094, createdName=12498568m60暂无昵称, createdTime=Fri Apr 19 14:54:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851845, encodeId=a07b18518455c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 23 00:54:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877086, encodeId=54c318e70865f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 05 13:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353073, encodeId=dea73530e3ae, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Nov 19 19:26:03 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286285, encodeId=070b1286285c7, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Nov 18 02:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]
    2018-11-19 青山颖钰

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1706551, encodeId=10eb1e06551f8, content=<a href='/topic/show?id=0df2e87477d' target=_blank style='color:#2F92EE;'>#结肠切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78747, encryptionId=0df2e87477d, topicName=结肠切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89f31292094, createdName=12498568m60暂无昵称, createdTime=Fri Apr 19 14:54:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851845, encodeId=a07b18518455c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Feb 23 00:54:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877086, encodeId=54c318e70865f, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Aug 05 13:54:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353073, encodeId=dea73530e3ae, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Nov 19 19:26:03 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286285, encodeId=070b1286285c7, content=<a href='/topic/show?id=d65b290333d' target=_blank style='color:#2F92EE;'>#免疫抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29033, encryptionId=d65b290333d, topicName=免疫抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Sun Nov 18 02:54:00 CST 2018, time=2018-11-18, status=1, ipAttribution=)]

相关资讯

Hepatol Res:危重症肝硬化患者的急性呼吸窘迫综合征的危险因素和结果

急性肝衰竭和休克是导致ARDS发展的危险因素,而肝硬化和酒精的病因则不是导致ARDS发展的危险因素。患有ARDS的肝硬化患者死亡率明显增加。早期识别和治疗感染对于改善患者的生存是重要的。